about
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisNovel Transthyretin Amyloid Fibril Formation Inhibitors: Synthesis, Biological Evaluation, and X-Ray Structural AnalysisTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeX-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitorsThe preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic stateMass spectrometry quantifies protein interactions--from molecular chaperones to membrane porins.Novel insights into protein misfolding diseases revealed by ion mobility-mass spectrometry.Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis.Beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrilsDistinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrilsSequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.Transthyretin Tyr77 familial amyloid polyneuropathy: a clinicopathological study of a large kindred.A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants.Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores.Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathyMeningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G)Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasmaTargeting protein aggregation for the treatment of degenerative diseasesC1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.Detection of metals and metalloproteins in the plasma of stroke patients by mass spectrometry methodsRepositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins.Autoimmune response to transthyretin in juvenile idiopathic arthritis.Localized structural fluctuations promote amyloidogenic conformations in transthyretin.Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysisStructural Changes Associated with Transthyretin Misfolding and Amyloid Formation Revealed by Solution and Solid-State NMR.Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).Inhibiting transthyretin amyloid fibril formation via protein stabilization.Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.Solid-State NMR Studies Reveal Native-like β-Sheet Structures in Transthyretin Amyloid.A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.Pathophysiology and treatment of cardiac amyloidosis.Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reportsCapture of a dimeric intermediate during transthyretin amyloid formation.Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen.Tissue-specific gene silencing monitored in circulating RNA.
P2860
Q26764754-66E55B4D-CDC7-492A-A991-9C82EFC09E53Q27656578-A0E41F29-D22F-4735-9A99-8A35C562B72FQ27679360-D46B5B2E-88FB-4A2C-AC61-E4F905470B97Q27701718-591E49FC-D02C-4786-AB25-47E1311A7D49Q28118516-AE06F0BC-B883-412C-99F4-7DAE918A385DQ30368236-8B2A6D56-F13D-4B28-8866-0C267C7FC6A3Q30426229-F6D541B3-67CA-4A90-9021-2355F41BEC3CQ33778710-7FC8A662-F992-4659-865E-AAD139E0AA36Q33891008-23A2CF7E-C0E4-4793-80FC-A83C17840404Q34416296-5782C28D-9265-4642-ADEE-CC3C80508FBCQ34443897-8B29FFCF-D31F-423B-8E06-DEE383E24AC9Q34475094-490F794E-CAE5-4BC1-B7CD-776D390FD99BQ34576022-600557F0-C36A-45E8-9030-F799EAC51152Q35066532-4269D90E-21E5-4325-A2D7-665389BFEDE5Q35280661-8DF8B7FA-662D-4AA5-9362-E6BF198BB620Q35690945-0221A785-70EA-4613-8A08-450103053C99Q35745590-202D81C4-B9D9-44E0-9788-2B7481249668Q35764345-ACFD2B05-229B-401C-83BF-49D1E77526E2Q35774204-3502C8FB-C0DC-4DCD-B91A-318A70666936Q35885902-56074757-3172-461E-96F5-119F5B59438AQ36235980-F987CE8E-9111-41F5-9C4C-4DF61E59AFFFQ36346078-936DB705-8A47-4B1A-9BB4-4A743B3FC934Q36539409-65C099F9-4580-4A0C-BE33-B899F1D2250AQ36615637-6C75ED3B-684C-42FB-BF07-FAEF98F30B4CQ36640504-DBE54283-C231-47AB-8F1A-E196CEA1D553Q36669011-9029CFE9-C018-4C62-BDD0-E7E680B540FEQ36675670-F803262E-4286-44E7-B26F-EB64A8865653Q36790516-3B9D7B5E-DC77-4DF8-B338-0523945CE3D8Q36996369-4F0E7D15-D1D4-48A7-8DCA-81B05647C136Q37082424-1CABEFEC-18A3-4905-8B1C-7E96F9137DD8Q37082709-4D97D229-D407-4DCA-AA03-EF8EEB4CF5B3Q37202287-835BB2D7-D76B-4E82-8528-57742D655104Q37280085-107AA959-FC47-43E2-9F00-A17D414A9688Q37514320-9367BBEC-B1EF-499C-91F9-38887A5C228EQ37975816-D4DC7C58-E47C-4CBB-8AB1-E508EBF6A49EQ38259728-EE16EEB9-26EE-4866-A1D3-75E9C3E586D9Q40488326-D63D7DF4-9716-4B9E-B114-824F9E189A83Q40784391-C720FE16-DCA7-4161-8D91-B440E9825A73Q41807915-6E8BF89A-1A76-4A45-8903-C41E20595706Q41878185-1EAC4D6B-35C8-40DF-BC3B-6E45C575B412
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Transthyretin mutations in health and disease.
@ast
Transthyretin mutations in health and disease.
@en
Transthyretin mutations in health and disease.
@nl
type
label
Transthyretin mutations in health and disease.
@ast
Transthyretin mutations in health and disease.
@en
Transthyretin mutations in health and disease.
@nl
prefLabel
Transthyretin mutations in health and disease.
@ast
Transthyretin mutations in health and disease.
@en
Transthyretin mutations in health and disease.
@nl
P356
P1433
P1476
Transthyretin mutations in health and disease
@en
P2093
Saraiva MJ
P304
P356
10.1002/HUMU.1380050302
P577
1995-01-01T00:00:00Z